摘要
探讨利拉鲁肽联合米格列醇治疗肥胖2型糖尿病患者的疗效。选取2017年6月~2018年5月该院收治的肥胖T2DM患者100例,采用随机数字表法将所有患者分为对照组(50例)和观察组(50例)。两组患者均给予糖尿病(Diabetes mellitus,DM)饮食、适量运动及接受DM教育,在此基础上对照组患者给予利拉鲁肽治疗,观察组在对照组基础上加用米格列醇治疗。比较两组临床疗效及不良反应发生情况,同时比较两组治疗前后空腹血糖(FPG)、餐后2h血糖(2hPG)、糖化血红蛋白(Hb A1c)、血清胆固醇(TC)及三酸甘油脂(TG),体重指数(BMI),胰岛功能指标及血清生长激素释放肽(Ghrelin)和视黄醇结合蛋白(RBP4)水平。与对照组(80%)比较,观察组总有效率(96%)显著升高(P<0.05)。治疗期间观察组和对照组不良反应发生率(8.00%vs 12.00%)比较差异无统计学意义(P>0.05)。治疗12周后,观察组BMI、FPG、2hPPG、Hb A1c、TC及TG水平均显著低于对照组,观察组INS、CP水平均显著高于对照组,观察组血清Ghrelin水平显著高于对照组,RBP4水平均显著低于对照组(P<0.05)。利拉鲁肽联合米格列醇可有效降低肥胖型T2DM患者体质量、血糖及血脂,改善胰岛素功能,提高血清Ghrelin水平,降低RBP4水平,且安全性可靠。
To investigate the efficacy of Lilarupeptide combined with MIG in the treatment of obese type 2 diabetes mellitus.From June 2017 to May 2018,100 obese T2 DM patients were treated in our hospital.The clinical efficacy and adverse reactions were compared between the two groups.At the same time,fasting blood glucose(FPG),2 h blood glucose(2 hPG),glycosylated hemoglobin(Hb A1 c),serum cholesterol(TC)and triacylglycerol(TG),body mass index(BMI),islet function and the level of growth hormone-releasing peptide(Ghrelin)and retinol-binding protein(RBP4)were compared between the two groups before and after treatment.Compared with control group(80%),the total effective rate in the observation group(96%)was significantly increased(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups during treatment(P>0.05).After 12 weeks of treatment,compared with control group,the levels of BMI,FPG,2 hPPG,Hb A1 c,TC and TG in the observation group were significantly decreased,the level of INS,CP in the observation group was significantly increased,the level of Ghrelin in the observation group was significantly increased,RBP4 in the observation group was significantly decreased(P<0.05).liraglutide combined with miglil alcohol can effectively reduce body mass,blood glucose and blood lipids in obese t2dm patients,improve insulin function,increase serum ghrelin levels,reduce rbp4 levels,and be safe and reliable.
作者
周蓓
潘婷
陈俊
赵云娟
ZHOU Bei;PAN Ting;CHEN Jun;ZHAO Yun-juan(Endocrinology Department,The Affiliated Jiangsu Shengze Hospital of Nanjing Medical University,Suzhou 215228,China)
出处
《药物生物技术》
CAS
2020年第3期236-239,共4页
Pharmaceutical Biotechnology
关键词
利拉鲁肽
米格列醇
肥胖
2型糖尿病
疗效
生长激素释放肽
视黄醇结合蛋白
Lilaruin
MIG alcohol Obesity
Type 2 diabetes mellitus
Curative effect
Growth hormone releasing peptide
Retinol binding protein
